Glioblastoma multiforme with oligodendroglial component (GBMO): Favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26)

BMC Cancer

Volumn 6, Issue , 2006, Pages

  Vordermark, Dirk ^a   Ruprecht, Klemens ^a   Rieckmann, Peter ^a   Roggendorf, Wolfgang ^a   Vince, Giles H ^a   Warmuth Metz, Monika ^a   Kölbl, Oliver ^a   Flentje, Michael ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD68 ANTIGEN; GLIAL FIBRILLARY ACIDIC PROTEIN; KI 67 ANTIGEN; NIMUSTINE; PROTEIN P53; TENIPOSIDE;

ADULT; AGED; ARTICLE; ASTROCYTOMA; BRAIN SURGERY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG WITHDRAWAL; FEMALE; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; KAPLAN MEIER METHOD; LEUKOPENIA; MALE; NEUROPATHOLOGY; OLIGODENDROGLIA; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PROGNOSIS; RADIATION DOSE; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CRANIOTOMY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; HUMANS; LIFE TABLES; MALE; MIDDLE AGED; NIMUSTINE; OLIGODENDROGLIA; OLIGODENDROGLIOMA; PROGNOSIS; RADIOTHERAPY, ADJUVANT; SURVIVAL ANALYSIS; TENIPOSIDE; TREATMENT OUTCOME;

EID: 33750715704     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-6-247     Document Type: Article

References (19)

1. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, Cavenee WK: The WHO classification of tumor of the nervous system. J Neuropathol Exp Neurol 2002, 61:215-225.
2. Cairncross G, Macdonald D, Ludwin S, Lee D, Cascino T, Buckner J, Fulton D, Dropcho E, Stewart D, Schold C Jr, et al.: Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Crin Oncol 1994, 12:2013-2021.
3. Heesters M, Molenaar W, Go GK: Radiotherapy in supratentorial gliomas. Strahlenther Onkol 2003, 179:606-14.
4. Nelson JS, Petito CK, Scott CB, Rotman M, Asbell S, Murray K: Glloblastoma with oligodendroglial features (GBM-OL): report from Radiation Therapy Oncology Group (RTOG) trial 8302 [abstract]. Lab Invest 1996, 75:141A.
5. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U. Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastama. N Engl J Med 2005, 352:987-996.
6. Stewart LA: Chemotherapy in adult high-grade glloma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002, 359:1011-1018.
7. Weller M, Muller B, Koch R, Bamberg M, Krauseneck P, Neuro-Oncology Working Group of the German Cancer Society: Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma. J Clin Oncol 2003, 21:3276-3284.
8. Kraus JA, Lamszus K, Glesmann N, Beck M, Wolter M, Sabel M, Krex D, Klockgether T, Relfenberger G, Schlegel U: Molecular genetic alterations in glloblastomas with oligodendroglial component. Acta Neuropathol 2001, 101:311-320.
9. Scott CB, Scarantino C, Urtasun R, Movsas B, Jones CU, Simpson JR, Fischbach AJ, Curran WJ Jr: Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. Int J Radiat Oncol Biol Phys 1998, 40:51-55.
10. van den Bent MJ, Delattre J, Brandes AA, Taphoom MJ, Hoang Xuan K, Bernsen H, Frenay M, Grisold W, Gorlia T, Lacombe D: First analysis of EORTC trial 26951, a randomized phase III study of adjuvant PCV chemotherapy in patients with highly anaplastic aligodendrogliama [abstract]. J Clin Oncol 2005, 23(suppl):A-1503.
11. Caincross G, Seiferheld W, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink K, Souhami L, Curran W Jr: An intergroup randomized controlled clinical trial (RCT) of chemotherapy plus radiation (RT) versus RT alone for pure and mixed anaplastic oligodendrogliomas: Initial report of RTOG 94-02 [abstract]. J Clin Oncol 2004, 23(suppl):A-1500.
12. Thiele W, Zunterer H, Maessen D, Flentje M, Oppitz U: Conventional vs. accelerated CT-planned irradiation of glioblastoma multiforme [abstract]. Radiother Oncol 2000, 56(suppl 1):27.
13. He J, Mokhtari K, Sanson M, Marie Y, Kujas M, Huguet S, Leuraud P, Capelle L, Delattre JY, Poirier J, Hoang-Xuan K: Glioblastomas with an oligodendroglial component: a pathological and molecular study. J Neuropathol Exp Neurol 2001, 60:863-871.
14. Nutt CL, Mani DR, Betensky RA, Tamayo P, Cairncross JG, Ladd C, Pohl U, Hartmann C, McLaughlin ME, Batchelor TT, Black PM, von Deimling A, Pomeroy SL, Golub TR, Louis DN: Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 2003, 63:1602-1607.
15. Vordermark D, Kölbl O, Ruprecht K, Vince GH, Bratengeier K, Flentje M: Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma. BMC Cancer 2005, 5:55.
16. Vordermark D, Kölbl O: Lack of survival benefit after stereotactic radiosurgery boost for glioblastoma multiforme: randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of radiation therapy oncology group 93-05 protocol: in regard to Souhami et al. (Int J Radiat Oncol Biol Phys 2004;60:853-860). Int J Radiat Oncol Biol Phys 2005, 62:296-297.
17. Abrey LE, Childs BH, Paleologos N, Kaminer L, Rosenfeld S, Salzmann D, Finlay JL, Gardner S, Peterson K, Hu W, Swinnen L, Bayer R, Forsyth P, Stewart D, Smith AM, Macdonald DR, Weaver S, Ramsey DA, Nimer SD, DeAngelis LM, Cairncross JG: High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma. J Neurooncol 2003, 65:127-134.
18. Pinto LW, Chimelli L: Oligodendroglial and neuronal component in glioblastomas: possible relation with prognosis [Portuguese]. Arq Neuropsiquiatr 2004, 62:1074-1078.
19. Hilton DA, Penney M, Pobereskin L, Sanders H, Love S: Histological Indicators of prognosis in glioblastomas: retinoblastoma protein expression and oligodendroglial differentiation indicate improved survival. Histopathology 2004, 44:555-560.